Table 1.
SARS Cov-2 variants and its impact on transmissibility and treatments.
| Variant name | Variant classification | WHO label | Country of Origin /Detection date | Spike protein substitutions | Attributes |
|---|---|---|---|---|---|
| B.1.1.7 | VOC | Alpha | United Kingdom/ December 2020 |
69del 70del 144del E484K S494P N501Y A570D D614G P681H T716I S982A D1118H K1191N |
↑ Transmissibility (∼50%) ↑ Severity ↑ Case fatality No impact on susceptibility to EUA monoclonal antibody treatments Minimal impact on neutralization by convalescent and post-vaccination sera |
| B.1.351 B.1.351.2 B.1.351.3 |
VOC | Beta | South Africa/ December 2020 |
D80A D215G 241del 242del 243del K417N E484K N501Y D614G A701V |
↑ Transmissibility (∼50%) ↓ Susceptibility to EUA monoclonal antibody treatments ↓ Neutralization to convalescent & post-vaccination sera |
| P.1 P.1.1 P.1.2 |
VOC | Gamma | Brazil/ January 2021 |
L18F T20N P26S D138Y R190S K417T E484K N501Y D614G H655Y T1027I |
↓ Susceptibility to bamlanivimab/etesevimab monoclonal antibody treatments ↓ Neutralization to convalescent & post-vaccination sera |
| B.1.617.2 AY.1 AY.2 |
VOI VOC VOC |
Delta | India/ May 2021 |
T19R V70F T95I G142D E156- F157- R158G (A222V W258L K417N L452R T478K D614G P681R D950N |
↑ Transmissibility ↓ Susceptibility to EUA monoclonal antibody treatments ↓ Neutralisation to post-vaccination sera |
| B.1.427 B.1.429 |
VOC | Epsilon | California/ July 2020 |
I4205V D1183Y S13I W152C L452R |
↑ Transmissibility (∼20%) ↓ susceptibility to EUA monoclonal antibody treatments ↓ neutralisation to convalescent & post-vaccination sera |
| B.1.1.529 | VOC | Omicron | South Africa\ November, 2021 |
A67V, del69-70, T95I, del142-144, Y145D, del211, L212I, ins214EPE T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |
↑ Transmissibility ↑ Risk of re-infection Deletion in the S gene, leading to S gene target failure (SGTF) in some PCR assays. SGTF can be used as a proxy marker to screen for Omicron. |
| B.1.525 | VOI | Eta | United Kingdom/Nigeria December 2020 | A67V 69del 70del 144del E484K D614G Q677H F888L |
↓ Susceptibility to EUA monoclonal antibody treatments ↓ Neutralization to convalescent & post-vaccination sera |
| B.1.526 | VOI | Iota | United States/ November 2020 |
L5F D80G T95I Y144- F157S D253G L452R S477N E484K D614G A701V T859N D950H Q957R |
↓ Susceptibility to bamlanivimab/ etesevimab monoclonal antibody treatments ↓ Neutralisation to convalescent & post-vaccination sera |
| B.1.617.1 | VOI | Kappa | India/ December 2020 |
T95I G142D E154K L452R E484Q D614G P681R Q1071H |
↓ Susceptibility to EUA monoclonal antibody treatments ↓ Neutralization to post-vaccination sera |
| C.37 | VOI | Lambda | Peru/ August 2020 |
G75V T76I Δ246-252 L452Q F490S D614G T859N |
Unclear data on transmissibility |
| B.1.621 | VOI | Mu | Colombia/ January 2021 |
R346K E484K N501Y D614G P681H |
↑ Transmissibility ↑ Susceptibility to infection |
| P.3 | VOI | Theta | Philippines/ January 2021 |
E484K N501Y D614G P681H |
↑ Transmissibility ↑ Susceptibility to infection |